Report from Annual General Meeting in SyntheticMR AB (publ)

The Annual General Meeting (AGM) of SyntheticMR AB (publ) was held on May 11, 2021, whereby the meeting resolved in accordance with the Nomination Committee and Board's proposed resolutions. The full resolutions are stated in the notice of the meeting.

The following resolutions were made at the AGM:

The AGM resolved to approve the Board's proposal that no dividend will be paid due to the 2020 result. The remaining capitalized funds of SEK 29,791,992 including the share premium reserve and retained earnings, are transferred in new accounts.

The AGM resolved to grant the Board of directors and CEO discharge.

The AGM decided that the Board should consist of 4 ordinary members and no deputies. The AGM resolved on the re-election of the Board members, Petra Apell Jan Bertus Marten (Marcel) Warntjes, Johan Sedihn and Staffan Persson. Further, the AGM decided to elect Johan Sedihn as the Chairman of the Board.

The AGM resolved that a Nomination Committee should be appointed by the Annual General Meeting instructing the Chairman of the Board to contact the three largest shareholders (hereby both direct registered shareholders and nominee-registered shareholders) in accordance with Euroclear Sweden AB's printout of the share register as of September 30, 2021.

The AGM resolved to amend the Articles of Association in accordance with the Board's proposal, which was presented in its entirety in the notice convening the Annual General Meeting.

The AGM resolved to split the company's shares, so-called share split, whereby one (1) existing share is divided into ten (10) shares. Following the completion of the share split, the number of shares will amount to 40,400,780. Furthermore, the AGM resolved that the Board or the person appointed by the Board be authorized to determine the record date and make the minor adjustments required for registration of the decision with the Swedish Companies Registration Office. The Board has decided that the record date for the split shall be 19 May 2021.

For further information, please contact Johanna Norén, CFO SyntheticMR AB, +46 70 619 21 00.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 6-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for MSK anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked and FDA 510(k) pending. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.